Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma.

ABSTRACT: Patients with glioblastoma have a very poor prognosis despite aggressive therapeutic strategies. Cytomegalovirus has been detected in >90% of glioblastoma tumors. This virus can affect tumor progression and may represent a novel glioblastoma therapy target. We report, here, a retrospective survival analysis of patients with secondary glioblastoma who were treated with the anti-viral drug valganciclovir at Karolinska University Hospital in Stockholm. We performed survival analyses of eight patients with secondary glioblastoma who were treated with a standard dose of valganciclovir as an add-on to second-line therapy after their disease progression to glioblastoma. Thirty-six patients with secondary glioblastoma admitted during the same time period who received similar treatment and care ser

SUBMITTER: Stragliotto G 

PROVIDER: S-EPMC7599902 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature